BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 19617248)

  • 1. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy.
    Beyer T; Diehl B; Randel G; Humpfer E; Schäfer H; Spraul M; Schollmayer C; Holzgrabe U
    J Pharm Biomed Anal; 2008 Sep; 48(1):13-9. PubMed ID: 18678460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
    Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
    Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
    Shen Y; Kang J
    Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple fluorescence assay for quantification of OSCS in heparin.
    Lühn S; Schiemann S; Alban S
    Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.
    Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of currently marketed heparin products: key tests for LMWH quality assurance.
    Ye H; Toby TK; Sommers CD; Ghasriani H; Trehy ML; Ye W; Kolinski RE; Buhse LF; Al-Hakim A; Keire DA
    J Pharm Biomed Anal; 2013 Nov; 85():99-107. PubMed ID: 23917037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2011 Jan; 54(2):337-44. PubMed ID: 20934294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy.
    Bigler P; Brenneisen R
    J Pharm Biomed Anal; 2009 May; 49(4):1060-4. PubMed ID: 19211212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of possible economically motivated adulterants in heparin sodium and low molecular weight heparins with a colorimetric microplate based assay.
    Sommers CD; Keire DA
    Anal Chem; 2011 Sep; 83(18):7102-8. PubMed ID: 21819047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
    Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
    Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method.
    Sitkowski J; Bednarek E; Bocian W; Kozerski L
    J Med Chem; 2008 Dec; 51(24):7663-5. PubMed ID: 19055319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and generic anticoagulants and biosimilars: safety considerations.
    Kalodiki E; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.